These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 29923015

  • 21. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, Childress AC.
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
    [Abstract] [Full Text] [Related]

  • 22. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M, Munda B, Svab V, Locatelli I.
    J Affect Disord; 2015 Jun 01; 178():149-59. PubMed ID: 25813457
    [Abstract] [Full Text] [Related]

  • 23. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC, Findling RL, Wu J, Kollins SH, Wang Y, Martin P, Robertson B.
    J Child Adolesc Psychopharmacol; 2020 Apr 01; 30(3):128-136. PubMed ID: 32233956
    [Abstract] [Full Text] [Related]

  • 24. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.
    Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, Adeyi B, Squires LA, Coghill D.
    CNS Drugs; 2013 Oct 01; 27(10):829-40. PubMed ID: 23893527
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
    Childress AC, Arnold V, Adeyi B, Dirks B, Babcock T, Scheckner B, Lasser R, Lopez FA.
    J Atten Disord; 2014 Feb 01; 18(2):123-32. PubMed ID: 22740112
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M, Giblin J, Gasior M, Gao J, Wigal T.
    Postgrad Med; 2011 May 01; 123(3):99-108. PubMed ID: 21566420
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
    Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Chan D, Childress A.
    J Manag Care Spec Pharm; 2024 Jun 01; 30(6):528-540. PubMed ID: 38824626
    [Abstract] [Full Text] [Related]

  • 34. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
    Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, Hodgkins P, Civil R, Coghill DR.
    CNS Drugs; 2014 Nov 01; 28(11):1059-69. PubMed ID: 25038977
    [Abstract] [Full Text] [Related]

  • 35. Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study.
    Søndergaard NR, Nørøxe KB, Carlsen AH, Randing SH, Warrer P, Thomsen PH, Clausen L.
    J Child Adolesc Psychopharmacol; 2024 Apr 01; 34(3):137-147. PubMed ID: 38608011
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.